首页 > 市场调查报告书 > 製药

勃起功能障碍药物市场规模、份额和成长分析（按类型、给药途径、通路和地区划分）—产业预测（2026-2033 年）

市场调查报告书

商品编码

1900266

勃起功能障碍药物市场规模、份额和成长分析（按类型、给药途径、通路和地区划分）—产业预测（2026-2033 年）

Erectile Dysfunction Drugs Market Size, Share, and Growth Analysis, By Type (Viagra (Sildenafil Citrate), Cialis (Tadalafil)), By Route of Administration, By Distribution Channel, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，治疗勃起功能障碍的药物市场规模将达到 28.6 亿美元，到 2025 年将增长至 31.2 亿美元，到 2033 年将增长至 63.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 9.2%。

勃起功能障碍（ED）发生率的上升是推动勃起功能障碍治疗市场成长的主要因素。这种影响相当一部分男性的疾病由多种因素引起，包括糖尿病、心血管疾病和心理压力。尤其值得注意的是，ED的盛行率与老龄化相关的生理变化和慢性疾病密切相关，而这些因素在老年人中日益普遍。身心健康之间的相互关联进一步加剧了这个问题，而多种药物也可能导致勃起功能障碍。药物输送技术的进步、人们对ED影响生活品质的认识不断提高以及医疗保健服务的改善，都在推动对有效药物解决方案的需求，因此，持续的研发对于市场扩张至关重要。

治疗勃起功能障碍药物的市场驱动因素

全球勃起功能障碍药物市场的主要驱动因素是性功能障碍盛行率的不断上升，而这又归因于人口老化、久坐不动的生活方式以及糖尿病和心血管疾病等慢性病发病率的增加。人们对这些性问题的认识和接受度不断提高，推动了对有效治疗方法的需求。此外，透过加强教育和沟通来消除对勃起功能障碍的歧视，有助于促进更开放的对话，并鼓励男性寻求医疗建议和治疗。因此，製药公司越来越重视开发创新治疗方法，进一步推动了市场成长。

限制勃起功能障碍治疗市场的因素

全球勃起功能障碍治疗市场的主要限制因素之一是人们对非药物疗法的认知度和接受度不断提高。随着越来越多的患者寻求包括生活方式调整、咨询和自然疗法在内的整体治疗方法，他们对传统药物的依赖性可能会降低。此外，对潜在副作用的担忧以及因治疗勃起功能障碍而产生的社会污名，也可能进一步抑制市场成长。另外，远端医疗服务的日益普及可能会促使患者更谨慎地探索替代疗法，从而降低对处方药的需求。这给市场上的现有製药公司带来了挑战。

勃起功能障碍治疗市场趋势

勃起功能障碍药物市场正经历重大变革，其驱动力包括非处方药（OTC）的出现和消费者获取途径的增加。这一趋势的特点是，製药公司积极研发和推广广受欢迎的非处方笺勃起功能障碍药物，旨在覆盖更广泛的客户群体，包括那些偏好非处方药购买方式的消费者，因为这种方式更加註重隐私和便利。这种演变在法规结构较为完善的地区尤其明显，反映出人们对勃起功能障碍药物的接受度不断提高，以及对男性健康问题的日益关注。最终，其目标是消除围绕治疗方案的偏见，并促进积极主动的健康管理。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）
Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）

简介目录

Product Code: SQMIG35I2259

Erectile Dysfunction Drugs Market size was valued at USD 2.86 Billion in 2024 and is poised to grow from USD 3.12 Billion in 2025 to USD 6.31 Billion by 2033, growing at a CAGR of 9.2% during the forecast period (2026-2033).

The rising incidence of erectile dysfunction (ED) is significantly propelling the growth of the erectile dysfunction drugs market. This condition, affecting a considerable percentage of men, is influenced by a range of factors such as diabetes, cardiovascular issues, and psychological stress. Notably, the prevalence of ED is closely tied to age-related physiological changes and chronic illnesses, which are increasingly common among older populations. The interconnected nature of physical and mental health further exacerbates this issue, with various medications potentially contributing to erectile difficulties. The demand for effective pharmaceutical solutions is increasing, driven by advancements in drug delivery technologies, greater awareness of ED's impact on quality of life, and enhanced healthcare access, making ongoing research and development critical for market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Erectile Dysfunction Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Erectile Dysfunction Drugs Market Segments Analysis

Global Erectile Dysfunction Drugs Market is segmented by Type, Route of Administration, and region. Based on Type, the market is segmented into Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), and Other Drugs. Based on Route of Administration, the market is segmented into Oral Mode of Administration, Injectable Mode of Administration, and Other Modes of Administration. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Erectile Dysfunction Drugs Market

A key market driver for the global erectile dysfunction drugs market is the increasing prevalence of sexual health disorders, driven by factors such as aging populations, sedentary lifestyles, and rising rates of chronic diseases like diabetes and cardiovascular issues. This growing awareness and acceptance of sexual health challenges have led to higher demand for effective treatment options. Additionally, the destigmatization of erectile dysfunction through improved education and communication fosters a more open dialogue, encouraging men to seek medical advice and treatment. As a result, pharmaceutical companies are increasingly focused on developing innovative therapies, further propelling market growth.

Restraints in the Erectile Dysfunction Drugs Market

One key market restraint for the global erectile dysfunction drugs market is the growing awareness and acceptance of non-pharmaceutical treatment options. As more patients seek holistic approaches, such as lifestyle modifications, counseling, and natural remedies, reliance on traditional medications may decline. Additionally, concerns regarding potential side effects and the stigma associated with seeking treatment for erectile dysfunction can further inhibit market growth. Moreover, the increasing preference for telehealth services allows patients to explore alternative treatments more discreetly, which can limit the demand for prescription medications, thereby posing a challenge to the established pharmaceutical players in the market.

Market Trends of the Erectile Dysfunction Drugs Market

The erectile dysfunction drugs market is witnessing a significant shift with the emergence of over-the-counter (OTC) options, enhancing accessibility for consumers. This trend is characterized by pharmaceutical companies actively pursuing the development and marketing of popular ED medications without the need for prescriptions. By doing so, they aim to tap into a wider demographic, catering to individuals who may prefer the privacy and convenience of OTC purchases. This evolution is particularly pronounced in regions with progressive regulatory frameworks, reflecting a broader acceptance of ED medications and a growing recognition of men's health issues, ultimately aiming to destigmatize treatment options and encourage proactive health management.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition

Erectile Dysfunction Drugs Market by Product

Market Overview
Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Other Drugs

Erectile Dysfunction Drugs Market by Route of Administration

Market Overview
Oral Mode of Administration
Injectable Mode of Administration
Other Modes of Administration

Erectile Dysfunction Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments